Unlike general health products stocked in every health store, CJC-1295 is distributed via a global research peptide market that Ādēt residents access almost entirely online. This online-only market structure is ultimately a quality advantage — top vendors differentiate through analytical documentation in ways local stores never could. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. The sections below cover what Ādēt researchers need to know about purchasing, testing, and working with CJC-1295 for legitimate research applications.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Ādēt researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The first step for any Ādēt researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — organic rankings are no guide to actual CJC-1295 quality. The HPLC chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be 98% or higher. For Ādēt researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is standard practice in the community. For Ādēt researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, order conservatively at first, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Ādēt
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the direct mitigation for this hazard. The research literature on CJC-1295 should be read critically before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
